These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25114808)

  • 21. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
    Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
    FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
    Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
    Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Widespread expression of BORIS/CTCFL in normal and cancer cells.
    Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
    PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells.
    Moscona R; Janssen SM; Elchebly M; Papadakis AI; Rubin E; Spatz A
    Pigment Cell Melanoma Res; 2023; 36(3-4):299-313. PubMed ID: 37082838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CTCFL/BORIS for the immunotherapy of cancer.
    Loukinov D
    Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
    Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
    Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.
    Janssen SM; Moscona R; Elchebly M; Papadakis AI; Redpath M; Wang H; Rubin E; van Kempen LC; Spatz A
    Cell Death Discov; 2020; 6():1. PubMed ID: 32123577
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
    Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The structural complexity of the human BORIS gene in gametogenesis and cancer.
    Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
    PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cell cycle role for the epigenetic factor CTCF-L/BORIS.
    Rosa-Garrido M; Ceballos L; Alonso-Lecue P; Abraira C; Delgado MD; Gandarillas A
    PLoS One; 2012; 7(6):e39371. PubMed ID: 22724006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.
    Teplyakov E; Wu Q; Liu J; Pugacheva EM; Loukinov D; Boukaba A; Lobanenkov V; Strunnikov A
    Oncotarget; 2017 Sep; 8(43):73448-73468. PubMed ID: 29088719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner.
    Sleutels F; Soochit W; Bartkuhn M; Heath H; Dienstbach S; Bergmaier P; Franke V; Rosa-Garrido M; van de Nobelen S; Caesar L; van der Reijden M; Bryne JC; van Ijcken W; Grootegoed JA; Delgado MD; Lenhard B; Renkawitz R; Grosveld F; Galjart N
    Epigenetics Chromatin; 2012 Jun; 5(1):8. PubMed ID: 22709888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
    Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
    Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.
    Renaud S; Loukinov D; Alberti L; Vostrov A; Kwon YW; Bosman FT; Lobanenkov V; Benhattar J
    Nucleic Acids Res; 2011 Feb; 39(3):862-73. PubMed ID: 20876690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BORIS in human cancers -- a review.
    Martin-Kleiner I
    Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The function of brother of the regulator of imprinted sites in cancer development.
    Zhou S; Li L; Zhang M; Qin Y; Li B
    Cancer Gene Ther; 2023 Feb; 30(2):236-244. PubMed ID: 36376421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.